A correlation between the risk of acute kidney injury and the usage of proton pump inhibitors with concomitant drugs.

Abstract

Worldwide, the use of proton pump inhibitors (PPIs) for the treatment of common gastrointestinal disorders such as gastroduodenal ulcers, acid-related dyspepsia, gastroesophageal reflux disease and Helicobacter pylori eradication has increased significantly. PPIs have been linked to both acute kidney injury (AKI) and chronic kidney disease (CKD); however, finding has only been evaluated in limited research with short follow-up periods. Case studies demonstrate how subtle symptoms of chronic proton pump inhibitor nephrotoxicity can make it challenging to diagnose. We discuss the pathogenesis and clinical presentations of proton pump inhibitor nephrotoxicity, as well as the epidemiological evidence that is currently available to support these findings. The study examined in experimental animals to see how PPI use related to incident AKI and CKD risk.